BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Toxopeus E, van der Schaaf M, van Lanschot J, Lagergren J, Lagergren P, van der Gaast A, Wijnhoven B. Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS). Ann Surg Oncol. 2018;25:2441-2448. [PMID: 29948420 DOI: 10.1245/s10434-018-6554-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Markar SR, van Berge Henegouwen MI. Reply to B. P. L. Wijnhoven et al and F. Nuytens et al. J Clin Oncol 2021;39:92-3. [PMID: 32946350 DOI: 10.1200/JCO.20.02354] [Reference Citation Analysis]
2 Wijnhoven BPL, Lagarde SM. Minimally Invasive Esophagectomy: Time to Reflect on Contemporary Outcomes. J Clin Oncol 2021;39:90-1. [PMID: 32946360 DOI: 10.1200/JCO.20.01620] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Huang WT, Lu HI, Wang YM, Chen YH, Lo CM, Lin WC, Lan YC, Tseng LH, Li SH. Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy. J Clin Med 2019;8:E1864. [PMID: 31684197 DOI: 10.3390/jcm8111864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Takahashi T, Kaneoka Y, Maeda A, Takayama Y, Seita K. Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma. Updates Surg 2021. [PMID: 34559400 DOI: 10.1007/s13304-021-01167-4] [Reference Citation Analysis]
5 Schapira MM, Stevens EM, Sharpe JE, Hochman L, Reiter JG, Calhoun SR, Shah SA, Bailey LC, Bagatell R, Silber JH, Tai E, Barakat LP. Outcomes among pediatric patients with cancer who are treated on trial versus off trial: A matched cohort study. Cancer 2020;126:3471-82. [PMID: 32453441 DOI: 10.1002/cncr.32947] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhang N, Zhang SW. Long-term effects of radiation prior to surgery and chemotherapy on survival of esophageal cancer undergoing surgery. Medicine (Baltimore) 2019;98:e17617. [PMID: 31651875 DOI: 10.1097/MD.0000000000017617] [Reference Citation Analysis]
7 Borggreve AS, van Rossum PSN, Mook S, Haj Mohammad N, van Hillegersberg R, Ruurda JP. Frequency of surgical resection after starting neoadjuvant chemoradiotherapy in patients with esophageal cancer: A population-based cohort study. Eur J Surg Oncol 2019;45:1919-25. [PMID: 30975447 DOI: 10.1016/j.ejso.2019.03.031] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Suo D, Wang L, Zeng T, Zhang H, Li L, Liu J, Yun J, Guan XY, Li Y. NRIP3 upregulation confers resistance to chemoradiotherapy in ESCC via RTF2 removal by accelerating ubiquitination and degradation of RTF2. Oncogenesis 2020;9:75. [PMID: 32839439 DOI: 10.1038/s41389-020-00260-4] [Reference Citation Analysis]
9 Satomi T, Kawano S, Inaba T, Nakagawa M, Mouri H, Yoshioka M, Tanaka S, Toyokawa T, Kobayashi S, Tanaka T, Kanzaki H, Iwamuro M, Kawahara Y, Okada H. Efficacy and safety of endoscopic submucosal dissection for gastric tube cancer: A multicenter retrospective study. World J Gastroenterol 2021; 27(11): 1043-1054 [PMID: 33776371 DOI: 10.3748/wjg.v27.i11.1043] [Reference Citation Analysis]
10 Pucher PH, Wijnhoven BPL, Underwood TJ, Reynolds JV, Davies AR. Thinking through the multimodal treatment of localized oesophageal cancer: the point of view of the surgeon. Curr Opin Oncol 2021;33:353-61. [PMID: 33966001 DOI: 10.1097/CCO.0000000000000751] [Reference Citation Analysis]
11 Niu Z, Zhang W, Shi J, Li X, Wu H. Effect of silencing C-erbB-2 on esophageal carcinoma cell biological behaviors by inhibiting IGF-1 pathway activation. J Cardiothorac Surg 2021;16:194. [PMID: 34233689 DOI: 10.1186/s13019-021-01540-9] [Reference Citation Analysis]
12 Paireder M, Jomrich G, Kristo I, Asari R, Rieder E, Beer A, Ilhan-Mutlu A, Preusser M, Schmid R, Schoppmann SF. Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity. Strahlenther Onkol 2020;196:779-86. [PMID: 32055873 DOI: 10.1007/s00066-020-01594-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Neumann PA, Berlet MW, Friess H. Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract. Expert Rev Anticancer Ther 2021;21:511-22. [PMID: 33355020 DOI: 10.1080/14737140.2021.1868991] [Reference Citation Analysis]
14 Wang HH, de Heer EC, Hulshoff JB, Kats-Ugurlu G, Burgerhof JGM, van Etten B, Plukker JTM, Hospers GAP; Dutch Upper Gastrointestinal Cancer Audit (DUCA) Group. Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis. Ann Surg Oncol 2021;28:3951-60. [PMID: 33249520 DOI: 10.1245/s10434-020-09372-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Moaven O, Wang TN. Combined Modality Therapy for Management of Esophageal Cancer: Current Approach Based on Experiences from East and West. Surg Clin North Am 2019;99:479-99. [PMID: 31047037 DOI: 10.1016/j.suc.2019.02.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]